Needham & Company LLC Raises Pacira BioSciences (NASDAQ:PCRX) Price Target to $32.00

Key Points

• Needham & Company raised Pacira BioSciences' price target from $30 to $32 and kept a "buy" rating, implying about a 25.54% upside from the prior close.
• Analyst coverage is mixed — three Buy, two Hold and one Sell — yielding a MarketBeat consensus rating of "Hold" and a consensus price target of $30.75, with individual targets ranging from $25 to $38.
• Pacira reported Q1 results that beat expectations (EPS $0.60 vs $0.55; revenue $177M vs $171.8M) and issued FY‑2026 revenue guidance of $745–$770M, but compressed margins and a high P/E keep near‑term investor caution.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) had its target price hoisted by Needham & Company LLC from $30.00 to $32.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Needham & Company LLC's price target would indicate a potential upside of 25.54% from the company's previous close.

Other research analysts have also issued reports about the company. Barclays dropped their price objective on Pacira BioSciences from $27.00 to $25.00 and set an "equal weight" rating for the company in a research note on Thursday, March 26th. HC Wainwright restated a "buy" rating and issued a $38.00 target price on shares of Pacira BioSciences in a research note on Friday, January 9th. Wall Street Zen lowered Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. Finally, Zacks Research upgraded Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 7th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $30.75.

Pacira BioSciences Stock Up 1.4%

Shares of PCRX stock opened at $25.49 on Friday. The stock has a market cap of $1.00 billion, a P/E ratio of 169.93 and a beta of 0.19. Pacira BioSciences has a one year low of $18.80 and a one year high of $27.64. The stock has a fifty day moving average price of $23.31 and a 200 day moving average price of $23.14. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.54 and a quick ratio of 3.28.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing the consensus estimate of $0.85 by ($0.28). Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The firm had revenue of $196.87 million during the quarter, compared to the consensus estimate of $201.93 million. During the same period last year, the business earned $0.91 earnings per share. The firm's revenue for the quarter was up 5.1% compared to the same quarter last year. Analysts predict that Pacira BioSciences will post 1.85 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Jonathan Slonin sold 3,261 shares of Pacira BioSciences stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total value of $74,416.02. Following the completion of the sale, the insider directly owned 223,640 shares in the company, valued at $5,103,464.80. This trade represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $20.81, for a total value of $83,240.00. Following the completion of the sale, the senior vice president owned 52,313 shares of the company's stock, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 32,261 shares of company stock worth $785,850 over the last three months. 6.40% of the stock is currently owned by company insiders.

Institutional Trading of Pacira BioSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC increased its position in Pacira BioSciences by 8.2% in the first quarter. Hsbc Holdings PLC now owns 19,922 shares of the company's stock worth $457,000 after purchasing an additional 1,506 shares during the period. Greenwood Capital Associates LLC boosted its holdings in Pacira BioSciences by 18.0% during the first quarter. Greenwood Capital Associates LLC now owns 22,795 shares of the company's stock worth $515,000 after buying an additional 3,471 shares during the last quarter. Inspire Investing LLC boosted its holdings in Pacira BioSciences by 25.7% during the first quarter. Inspire Investing LLC now owns 22,574 shares of the company's stock worth $510,000 after buying an additional 4,616 shares during the last quarter. Foster & Motley Inc. boosted its holdings in Pacira BioSciences by 38.8% during the first quarter. Foster & Motley Inc. now owns 57,000 shares of the company's stock worth $1,288,000 after buying an additional 15,943 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in Pacira BioSciences during the first quarter worth about $411,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences News Roundup

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Q1 results beat expectations — Pacira reported $0.60 EPS vs. $0.55 consensus and revenue of $177M vs. $171.8M consensus; revenue rose ~5% YoY and EXPAREL volumes grew ~7%, signaling continued commercial recovery. Read More.
• Positive Sentiment: Pipeline and clinical milestones are advancing — company completed enrollment in the Phase 3 shoulder osteoarthritis study for ZILRETTA (topline readout expected by year-end) and is progressing PCRX-201 Phase II work, which supports future growth optionality beyond branded injectables. Read More.
• Neutral Sentiment: FY‑2026 revenue guidance set to $745M–$770M (consensus ~ $761.5M) — guidance range brackets the street forecast but sits slightly below the consensus midpoint, leaving modest near‑term upside/ downside risk depending on execution. Read More.
• Negative Sentiment: Uncertainty on margins/valuation and lack of explicit EPS guidance increase short‑term investor caution — net margin remains compressed and the stock trades at a high P/E, which could amplify reactions to any execution slips or weaker guidance cadence. Read More.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.